African Clinical Trial Ethics Committees: Capacity Building & AVAREF Insights
This article delves into the vital role of African Clinical Trial Ethics Committees in capacity building, highlighting AVAREF's insights on ethical drug development.
Quick Answer
This article delves into the vital role of African Clinical Trial Ethics Committees in capacity building, highlighting AVAREF's insights on ethical drug development.
Key Questions
- What is AVAREF and when was it established?
- How does AVAREF strengthen ethics committees?
- What countries participate in AVAREF?
- What are the key AVAREF guidelines for clinical trials?
- How does AVAREF contribute to the African Medicines Agency?
The African Vaccine Regulatory Forum (AVAREF) strengthens Clinical Trial Ethics Committees across Africa through WHO-hosted training, joint reviews, and harmonized standards. Established in 2006, this network now supports all 55 African member states with standardized tools that reduce review timelines and improve oversight quality for clinical research.
Contents9 sections
Key Takeaways
- WHO-established network: AVAREF was created in 2006 by WHO to build regulatory and ethics capacity for clinical trials, emerging from a joint review of a meningococcal vaccine trial.
- All 55 African countries: The network includes all African member states, with approximately 40 countries actively participating in multi-country joint reviews for clinical trial applications.
- Standardized regulatory tools: AVAREF guidelines include templates for trial applications, GCP inspection checklists, and joint review protocols endorsed in October 2019.
- Capacity building programs: Training includes thematic workshops, hands-on practice for reviewers, optimization missions, and specialized webinars. Africa's pandemic trial networks show how capacity building enables rapid response.
- AMA integration: AVAREF is positioned to support the new African Medicines Agency (AMA) with established harmonization frameworks and technical expertise.
What Is AVAREF and Why Was It Created?
The African Vaccine Regulatory Forum (AVAREF) addresses a fundamental gap in African clinical research. Before 2006, many countries lacked systems for approving and overseeing clinical trials. Ethics committees faced resource constraints and fragmented standards. South Africa's growing trial portfolio shows how improved ethics capacity attracts research investment.
WHO established AVAREF in 2006 following a joint review of a clinical trial application for a group A meningococcal conjugate vaccine. This collaboration revealed the potential for coordinated regulatory approaches. The subsequent joint GCP inspection of the vaccine's phase II trial demonstrated that African regulators could effectively oversee complex trials when working together.
The initiative began with 23 countries targeted for HIV, malaria, and tuberculosis vaccine trials. Today it encompasses all 55 African member states. AVAREF's mandate expanded beyond vaccines in 2016 to include medicines and medical products, reflecting its success and growing relevance to African health security.
How Does AVAREF Strengthen Ethics Committees?
AVAREF employs multiple strategies to build ethics committee capacity. The approach combines training, standardization, and hands-on collaboration.
Training programs form the foundation. AVAREF delivers thematic workshops on ethical review methodologies, regulatory compliance frameworks, and informed consent best practices. Hands-on practice sessions allow reviewers and inspectors to apply guidelines to real trial applications. Specialized webinars provide continuous learning opportunities for committee members who cannot travel to in-person events.
Optimization missions assess national clinical research ecosystems. During these missions, AVAREF engages regulators, investigators, ethics committees, and research institutions to identify strengths and gaps. Follow-up support ensures sustained progress. These missions apply ICH-GCP standards, WHO benchmarking tools, and AVAREF guidelines.
Standardized tools reduce variability in review quality. The AVAREF Guidelines and regulatory tools include:
- Standardized templates and checklists for clinical trial application submission and assessment
- Guide and checklist for Good Clinical Practice (GCP) Inspection
- Guideline for joint review of clinical trial applications
- Guideline and application form for compassionate use access
The Technical Coordination Committee and Steering Committee developed these tools. The AVAREF Assembly endorsed them in Victoria Falls, Zimbabwe, in October 2019.
What Governance Structure Supports AVAREF?
AVAREF operates through a multi-layered governance structure designed to balance technical expertise with member state ownership.
The Assembly of all Member States provides ultimate authority. This body ensures that AVAREF activities align with national priorities and regional health needs. Member states participate through regular needs assessments, direct requests, surveys, and feedback during AVAREF events.
The Steering Committee represents Regional Economic Communities (RECs). It defines policies, strategies, and plans for AVAREF. The committee oversees implementation by member states and ensures accountability for strategic objectives.
The Technical Coordinating Committee serves as the scientific and technical advisory body. It advises the Steering Committee and Assembly on scientific strategies, directions, and priorities. This committee ensures that AVAREF standards reflect current regulatory science and best practices.
The Secretariat, hosted by WHO Regional Office for Africa, coordinates day-to-day operations. WHO acts as facilitator, coordinator, and supporter of the network. The Secretariat mobilizes funding and ensures that workplans approved by member states receive implementation support.
What Impact Has AVAREF Achieved?
AVAREF's contributions extend across multiple disease areas and public health emergencies. The network has accelerated access to vaccines against meningitis, malaria, tuberculosis, Ebola, and COVID-19.
During the 2014-2016 West Africa Ebola epidemic, AVAREF served as the platform for ethics and regulatory oversight of vaccine clinical trials. The network prioritized regulatory oversight with support from the US FDA, European Medicines Agency, and Health Canada. African National Regulatory Authorities undertook joint and assisted reviews of clinical trial applications, expediting decisions during a health emergency.
AVAREF played a similar role during the COVID-19 pandemic. The network facilitated swift regulatory review and emergency use authorization decisions for COVID-19 vaccines across Africa. This demonstrated the maturity of African regulatory coordination and the value of pre-established harmonization frameworks.
The Pan African Medical Journal has documented AVAREF's contributions in a dedicated supplement. Articles cover joint reviews, regulatory harmonization tools, and the path forward in the African Medicines Agency era. Authors include AVAREF leadership, WHO representatives, Bill & Melinda Gates Foundation staff, and participating African member state officials.
What Is the AVAREF Strategic Roadmap?
AVAREF has developed a Strategic Roadmap 2025-2035 to guide its next decade of operation. This roadmap addresses evolving African health needs and the emerging African Medicines Agency.
The Ecosystem Survey 2025 provides the evidence base for this planning. This annual continent-wide initiative maps the state of clinical trial oversight across Africa. It captures how National Regulatory Authorities and Ethics Committees operate, including review timelines, staffing, digital systems, and emergency preparedness. The survey tracks progress using a standardized monitoring framework.
Key focus areas for the strategic period include:
| Priority Area | Objective | Target Outcome |
|---|---|---|
| Review Timelines | Track year-on-year changes in CTA processing | Reduced median review times across member states |
| Regulatory Capacity | Monitor staffing and institutional readiness | Sustained technical expertise in NRAs and NECs |
| Digital Systems | Measure progress in digital readiness | Electronic submission and review platforms |
| Preparedness | Assess emergency response capacity annually | Rapid regulatory response to health emergencies |
The ecosystem approach connects researchers, ethics committees, trial sites, regulators, manufacturers, and patients across all 55 African countries. This life-cycle perspective ensures that capacity building aligns with product development stages from research through post-market surveillance.
How Does AVAREF Relate to the African Medicines Agency?
The African Medicines Agency (AMA) represents a new continental regulatory body. AVAREF is positioned to play a critical role in establishing AMA's clinical trial oversight functions.
Harmonization efforts under AVAREF provide a foundation for AMA integration. Common technical requirements, standardized review processes, and established collaboration mechanisms between NRAs and ethics committees create the infrastructure for continental regulatory coherence.
The Addis Ababa meeting in June 2016 established a new governance model expressly designed to support the future African Medicines Agency. Heads of National Regulatory Authorities and Ethics Committees endorsed this model, recognizing that effective continental regulation requires strong national capacity. Cross-border harmonization efforts in the East African Community demonstrate this principle at work.
Challenges remain. Funding sustainability depends on continued support from regulatory authorities, international donors, and industry partnerships. Retention of trained ethics committee members requires competitive compensation and professional development opportunities. Full regulatory harmonization will require political will from national authorities to align divergent national requirements.
Frequently Asked Questions
What is AVAREF and when was it established?
The African Vaccine Regulatory Forum (AVAREF) is a WHO-established network launched in 2006 to strengthen regulatory and ethics capacity for clinical trials across Africa. It began with a joint review of a meningococcal vaccine trial and has since expanded to support all 55 African member states with standardized tools and training.
How does AVAREF strengthen ethics committees?
AVAREF strengthens ethics committees through dedicated training programs, optimization missions, standardized review templates, and joint review processes. The initiative provides hands-on practice for reviewers, thematic workshops, and webinars for continuous learning, all aligned with ICH-GCP standards and WHO benchmarking tools.
What countries participate in AVAREF?
All 55 African member states are part of AVAREF. Approximately 40 countries actively participate in activities such as multi-country joint reviews for clinical trial applications. The network includes National Regulatory Authorities and National Ethics Committees from across the continent.
What are the key AVAREF guidelines for clinical trials?
AVAREF has developed standardized templates and checklists for clinical trial application submission and assessment, guides and checklists for Good Clinical Practice (GCP) inspections, guidelines for joint review of clinical trial applications, and guidelines for compassionate use access. These tools were endorsed by the AVAREF Assembly in Victoria Falls, Zimbabwe, in October 2019.
How does AVAREF contribute to the African Medicines Agency?
AVAREF is positioned to play a critical role in establishing clinical trial oversight functions for the new African Medicines Agency (AMA). The network's harmonized standards and capacity-building infrastructure provide a foundation for continental regulatory integration.
Primary Sources
- World Health Organization Regional Office for Africa. African Vaccine Regulatory Forum (AVAREF) - Overview. https://www.afro.who.int/health-topics/immunization/avaref/overview. Accessed 2026.
- AVAREF. Guidelines and Regulatory Tools. https://avaref.afro.who.int/guidelines/. Accessed 2026.
- AVAREF. Supporting Countries - Capacity Strengthening. https://avaref.afro.who.int/member-country-support/. Accessed 2026.
- AVAREF. FAQs. https://avaref.afro.who.int/faqs/. Accessed 2026.
- AVAREF. Ecosystem and Strategic Roadmap. https://avaref.afro.who.int/ecosystem/. Accessed 2026.
- Pan African Medical Journal. AVAREF Supplement: Two Decades of AVAREF: Successes, Lessons, and the Path Forward. https://www.panafrican-med-journal.com/content/series/52/2/. Accessed 2026.
- WHO African Region. 6th Meeting of AVAREF: AVAREF Broadened Beyond Vaccines. https://www.afro.who.int/news/6th-set-meetings-african-vaccine-regulatory-forum-avaref-avaref-broadened-beyond-vaccines. Published 2016.
- AVAREF. Strategic Plan 2018-2020. https://www.afro.who.int/sites/default/files/2018-07/2018-2020_Avaref_Strategic_Plan.pdf. Published 2018.
Related coverage: Regulatory Harmonization Impact on Cross-Border Clinical Trial Approvals in EAC | Pandemic Trial Networks Repurposed: Africa's COVID-19 Legacy | HIV Clinical Trials Africa: IMPALA Trial Validates CAB/RPV LA Efficacy
This article follows our editorial standards. Report a correction via editorial contact.
